TY - JOUR
T1 - Early intervention for obsessive compulsive disorder
T2 - An expert consensus statement
AU - Fineberg, Naomi A.
AU - Dell'Osso, Bernardo
AU - Albert, Umberto
AU - Maina, Giuseppe
AU - Geller, Daniel
AU - Carmi, Lior
AU - Sireau, Nick
AU - Walitza, Susanne
AU - Grassi, Giacomo
AU - Pallanti, Stefano
AU - Hollander, Eric
AU - Brakoulias, Vlasios
AU - Menchon, Jose M.
AU - Marazziti, Donatella
AU - Ioannidis, Konstantinos
AU - Apergis-Schoute, Annemieke
AU - Stein, Dan J.
AU - Cath, Danielle C.
AU - Veltman, Dick J.
AU - Van Ameringen, Michael
AU - Fontenelle, Leonardo F.
AU - Shavitt, Roseli G.
AU - Costa, Daniel
AU - Diniz, Juliana B.
AU - Zohar, Joseph
N1 - Funding Information:
The European College of Neuropsychopharmacology (ECNP) OCRN is one component of the ECNP-Network Initiative (ECNP-NI) and receives financial support from the ECNP, to support its academic activities. The ECNP had no role whatsoever in the writing of this review paper, nor in the decision to submit the paper for publication. All authors agreed on the title, scope and content of the manuscript, contributed to the literature searches, and approved the final manuscript. Each author led on the writing of a section or part of a section of the manuscript. Specifically NAF and DJS led on writing the introduction; NAF and MVA ? epidemiology; NS ? vignette; BDO - duration of untreated illness; UA and GM ? early intervention; DG and SW - intervention in childhood; LC and KI? digital methods; GG and SP ? immunology; EH ? spectrum disorders; VB-prevention; JM and DM-cost and burden; AA and DV? brain imaging and habit; LF, DS, DC and JD ? intervention in LMIC; JZ, NAF and DC? integration. NAF composed the first and final drafts of the manuscript. Dr. Fineberg reports having received within the past 3 years, personal fees from Lundbeck, Otsuka, Abbott, Sun Pharma, Taylor and Francis; personal fees and non-financial support from Wiley; grants from the NIHR, Wellcome Institute; grants and non-financial support from the EU, ECNP, Shire; non-financial support from the BAP, WHO, CINP, RCPsych, ISAD, International College Of OC Spectrum Disorders, IFMAD, MHRA; royalties from Oxford University Press, all outside the submitted work. Dr Fineberg leads a treatment service for OCD and is involved in several consumer charities for people with OCD. Dr. Geller has no conflicts of interest with respect to this manuscript. He has received funding from the National Institute of Mental Health, The American Academy of Child and Adolescent Psychiatry, Biohaven Pharmaceuticals, and Neurocrine Bioscience in the last 3 years and lifetime from Eli Lilly, GlaxoSmithKline, Pfizer, Otsuka, Boehringer-Ingelheim, Allergan and Lundbeck. Dr Stein has in the past 3 years received research grants and/or consultancy honoraria from Biocodex, Lundbeck, Servier, and Sun. Dr Maina has received funding from in the last 3 years from Janssen, Lundbeck, Otsuka, Angelini and FbHealth, all outside the submitted work. Dr. Walitza has received lecture honoraria from Opopharma in the last 5 years. Her work was supported in the last 5 years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM High Specialized Medicine of the Kanton Zurich, Switzerland, Bfarm Germany, Zinep, Hartmann M?ller Stiftung, Olga Mayenfisch. Dr. Walitza leads a treatment service for childhood OCD and is Vice President of the Swiss Society for OCD. Outside professional activities and interests are declared under the link of the University of Zurich www.uzh.ch/prof/ssl-dir/interessenbindungen/client/web/. Dr Fontenelle has no conflicts of interest with respect to this manuscript. He has received grants from Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (#308237/2014-5), Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiro (#E-26/203.052/2017), Instituto D'Or de Ensino e Pesquisa (IDOR) and Cambridge University Press. Prof. Stefano Pallanti has no conflicts of interest for this paper. In the past 12 months, he received a grant by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R21DA042271. In the last 3 years, Dr Dell'Osso received speaker fees from Lundbeck, Angelini and FB Health. He has no other interests or affiliations to disclose that may pose a conflict with the content of the article. Dr. Van Ameringen reports being on the Advisory Boards of Allergan, Almatica, Lundbeck, Otsuka and Purdue; he is on the Speaker's Bureau for Allergan, Lundbeck, Pfizer and Purdue; he has received research support from Janssen-Ortho Inc, Pfizer, Shire Canada, the Canadian Foundation for Innovation and Hamilton Academic Health Sciences Organization (HAHSO). Dr. Daniel Costa has no conflicts of interest with respect to this manuscript. He reports having received within the past 12 months personal fees from Pfizer and Libbs. Dr. Menchon has no conflicts of interest with respect to this manuscript. He has received funding from the Instituto Carlos III, AGAUR, AB Biotics, Janssen, and Servier in the last 3 years. Dr Juliana Belo Diniz has received honoraria from Janssen Pharmaceutics (speaker) and Pfizer (consultant) unrelated to this manuscript. Dr. Hollander reports receiving research grants FD-R-05106-01-A4; NCT03197662 (PI: Hollander), FDA, Orphan ProductsDivision AR160104; NCT03202303 (PI: Eric Hollander), DOD CDMRP Autism Research Program Clinical Trial Award. Dr. Brakoulias, Dr. Carmi, Dr. Albert, Dr. Veltman, Mr. Sireau, Dr. Shavitt, Dr. Cath, Dr. Marazziti, Dr. Grassi have no conflicts of interest with respect to this manuscript. We are grateful to members of the European College of Neuropsychopharmacology (ECNP) Obsessive Compulsive and Related Disorders Research Network (OCRN) the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the World Psychiatric Association Anxiety and Obsessive Compulsive Disorders Section whose comments have shaped this document in its development. The European College of Neuropsychopharmacology (ECNP) OCRN is one component of the ECNP-Network Initiative (ECNP-NI) and receives financial support from the ECNP, to support its academic activities.
Funding Information:
We are grateful to members of the European College of Neuropsychopharmacology (ECNP) Obsessive Compulsive and Related Disorders Research Network (OCRN) the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the World Psychiatric Association Anxiety and Obsessive Compulsive Disorders Section whose comments have shaped this document in its development. The European College of Neuropsychopharmacology (ECNP) OCRN is one component of the ECNP-Network Initiative (ECNP-NI) and receives financial support from the ECNP, to support its academic activities.
Publisher Copyright:
© 2019
PY - 2019/4
Y1 - 2019/4
N2 - Obsessive-compulsive disorder (OCD) is common, emerges early in life and tends to run a chronic, impairing course. Despite the availability of effective treatments, the duration of untreated illness (DUI) is high (up to around 10 years in adults) and is associated with considerable suffering for the individual and their families. This consensus statement represents the views of an international group of expert clinicians, including child and adult psychiatrists, psychologists and neuroscientists, working both in high and low and middle income countries, as well as those with the experience of living with OCD. The statement draws together evidence from epidemiological, clinical, health economic and brain imaging studies documenting the negative impact associated with treatment delay on clinical outcomes, and supporting the importance of early clinical intervention. It draws parallels between OCD and other disorders for which early intervention is recognized as beneficial, such as psychotic disorders and impulsive-compulsive disorders associated with problematic usage of the Internet, for which early intervention may prevent the development of later addictive disorders. It also generates new heuristics for exploring the brain-based mechanisms moderating the ‘toxic’ effect of an extended DUI in OCD. The statement concludes that there is a global unmet need for early intervention services for OC related disorders to reduce the unnecessary suffering and costly disability associated with under-treatment. New clinical staging models for OCD that may be used to facilitate primary, secondary and tertiary prevention within this context are proposed.
AB - Obsessive-compulsive disorder (OCD) is common, emerges early in life and tends to run a chronic, impairing course. Despite the availability of effective treatments, the duration of untreated illness (DUI) is high (up to around 10 years in adults) and is associated with considerable suffering for the individual and their families. This consensus statement represents the views of an international group of expert clinicians, including child and adult psychiatrists, psychologists and neuroscientists, working both in high and low and middle income countries, as well as those with the experience of living with OCD. The statement draws together evidence from epidemiological, clinical, health economic and brain imaging studies documenting the negative impact associated with treatment delay on clinical outcomes, and supporting the importance of early clinical intervention. It draws parallels between OCD and other disorders for which early intervention is recognized as beneficial, such as psychotic disorders and impulsive-compulsive disorders associated with problematic usage of the Internet, for which early intervention may prevent the development of later addictive disorders. It also generates new heuristics for exploring the brain-based mechanisms moderating the ‘toxic’ effect of an extended DUI in OCD. The statement concludes that there is a global unmet need for early intervention services for OC related disorders to reduce the unnecessary suffering and costly disability associated with under-treatment. New clinical staging models for OCD that may be used to facilitate primary, secondary and tertiary prevention within this context are proposed.
KW - Compulsive
KW - Duration of untreated illness
KW - Early intervention
KW - OCD
KW - Obsessive
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=85061443166&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2019.02.002
DO - 10.1016/j.euroneuro.2019.02.002
M3 - Article
C2 - 30773387
AN - SCOPUS:85061443166
SN - 0924-977X
VL - 29
SP - 549
EP - 565
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 4
ER -